文献速递淋巴瘤

177Lu-lilotomab治疗B细胞非霍奇金淋巴瘤的疗效与G2/M期细胞周期阻滞调控相关

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.
PubMed 文献 · Leukemia · 2019-12-13

该临床前研究探讨了抗CD37抗体-放射性核素偶联物177Lu-lilotomab在B细胞非霍奇金淋巴瘤(NHL)模型中的疗效。在SCID小鼠DOHH2(转化性滤泡性淋巴瘤)异种移植瘤中,低活性(100 MBq/kg)即可显著延迟肿瘤生长;而OCI-Ly8(弥漫大B细胞淋巴瘤)或Ramos(伯基特淋巴瘤)异种移植瘤需提高至500 MBq/kg才显示显著延迟。DOHH2细胞对177Lu-lilotomab高度敏感,与G2/M期阻滞减少、WEE-1和MYT-1介导的CDK1磷酸化降低及凋亡增加相关;联合G2/M期阻滞抑制剂(MK-1775和PD-166285)可增强体外、体内及患者样本中的疗效。

要点

  • 177Lu-lilotomab在转化性滤泡性淋巴瘤模型中低活性(100 MBq/kg)即显著延迟肿瘤生长。
  • DOHH2细胞高敏感性机制涉及G2/M期阻滞减少、CDK1磷酸化降低和凋亡增加。
  • 联合G2/M期阻滞抑制剂可增强177Lu-lilotomab的体外、体内及患者样本疗效。

核心结论

  • 177Lu-lilotomab对CDK1抑制性磷酸化水平低的肿瘤(如转化性滤泡性淋巴瘤)尤为有效。

研究设计与样本

  • 临床前研究,在SCID小鼠DOHH2异种移植瘤、athymic小鼠OCI-Ly8和Ramos异种移植瘤中评估177Lu-lilotomab疗效,并进行克隆形成和增殖实验及患者样本检测。

主要发现

  • 在DOHH2异种移植瘤中,177Lu-lilotomab在100 MBq/kg活性下显著延迟肿瘤生长。
  • 在OCI-Ly8或Ramos异种移植瘤中,需500 MBq/kg活性才显示显著肿瘤生长延迟。
  • DOHH2细胞对177Lu-lilotomab高度敏感,Ramos细胞敏感性最低,U2932、OCI-Ly8和Rec-1细胞敏感性中等。
  • DOHH2细胞中强细胞毒性与G2/M期阻滞减少、WEE-1和MYT-1介导的CDK1磷酸化降低及凋亡增加相关。
  • 联合MK-1775或PD-166285可增强177Lu-lilotomab在体外、体内及患者样本中的疗效。

临床怎么用

  • 对于CDK1抑制性磷酸化水平低的B细胞NHL(如转化性滤泡性淋巴瘤),177Lu-lilotomab可能是一种有效治疗选择。
  • 联合G2/M期细胞周期阻滞抑制剂可能提高177Lu-lilotomab的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 (177Lu)-lilotomab (Betalutin®) was investigated in preclinical models of NHL. In SCID mice bearing DOHH2 (transformed follicular lymphoma, FL) cell xenografts, 177Lu-lilotomab significantly delayed tumor growth, even at low activity (100 MBq/kg). In athymic mice bearing OCI-Ly8 (diffuse large B-cell lymphoma, DLBCL) or Ramos (Burkitt's lymphoma) cell xenografts, 177Lu-lilotomab activity had to be increased to 500 MBq/kg to show a significant tumor growth delay. Clonogenic and proliferation assays showed that DOHH2 cells were highly sensitive to 177Lu-lilotomab, while Ramos cells were the least sensitive, and U2932 (DLBCL), OCI-Ly8, and Rec-1 (mantle cell lymphoma) cells displayed intermediate sensitivity. The strong 177Lu-lilotomab cytotoxicity observed in DOHH2 cells correlated with reduced G2/M cell cycle arrest, lower WEE-1- and MYT-1-mediated phosphorylation of cyclin-dependent kinase-1 (CDK1), and higher apoptosis. In agreement, 177Lu-lilotomab efficacy in vitro, in vivo, and in patient samples was increased when combined with G2/M cell cycle arrest inhibitors (MK-1775 and PD-166285). These results indicate that 177Lu-lilotomab is particularly efficient in treating tumors with reduced inhibitory CDK1 phosphorylation, such as transformed FL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pichard A, Marcatili S, Karam J, et al. The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2019. PMID: 31836849. doi:10.1038/s41375-019-0677-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。